Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

This phase 2 clinical trial, published in the New England Journal of Medicine, evaluated orforglipron as a treatment for obesity in adults without diabetes. The randomized, double-blind, placebo-controlled study included 272 participants with BMI >=30 (or >=27 with comorbidity) who were randomized to different doses of oral orforglipron or placebo for 36 weeks.

The results were impressive and comparable to those obtained with injectable GLP-1 agonists:

• 36 mg dose: -9.4% weight loss
• 45 mg dose: -12.6% weight loss
• Highest dose (escalated): -14.7% weight loss
• Placebo: -2.3% weight loss

The 14.7% weight loss in just 36 weeks with an oral medication is particularly significant, as it approaches the results obtained with injectable semaglutide 2.4 mg weekly (approximately 15% in 68 weeks in the STEP 1 study), but in a shorter period and without the need for injections.

Beyond weight loss, participants showed significant improvements in waist circumference, blood pressure, triglycerides, and inflammatory markers. Gastrointestinal adverse events (nausea, vomiting) were the most common, but most were mild to moderate and diminished over time.

Orforglipron, developed by Eli Lilly, represents a potential paradigm shift in the treatment of obesity: for the first time, an oral GLP-1 agonist demonstrated efficacy comparable to injectables for weight loss, potentially democratizing access to this therapeutic class and significantly improving treatment adherence.